Alamar Citations
Total Number of Publications
Publications This Year
Publications Last Month
Cross-Platform Comparison of Highly Sensitive Immunoassays for Inflammatory Markers in a COVID-19 Cohort
Abe, Beer, Nguyen et al
J Immunol (2024)
Abe, Beer, Nguyen et al
J Immunol (2024)
Cited by 20
Snippet: JM are employees and stock holders of Alamar Biosciences, Inc. YL and WF were named inventors in a patent application for the NULISA technology filed by Alamar Biosciences, Inc
Olink and NULISAseq Proteomic Technologies Applied to a COVID-19-Induced Acute Respiratory Distress Syndrome (ARDS) Case-Control Study Revealed High Similarity and Complementarity and Shed Light on the Cytokine Storm
Taleb, Stephan, Chennakkandathil et al
SSRN (2024)
Taleb, Stephan, Chennakkandathil et al
SSRN (2024)
Cited by 2
Snippet: NULISAseq assays were performed at Alamar Biosciences as described previously (22). 208 log2 transformed to obtain NULISA Protein Quantification (NPQ) units for downstream 241
A novel automated multiplex immunoassay for the ultrasensitive detection of blood‐based biomarkers for neurodegenerative diseases
Ma, Ariyapala, Alganem et al
Alzheimer's & Dementia (2023) 19 (S24) DOI: 10.1002/alz.082794
Ma, Ariyapala, Alganem et al
Alzheimer's & Dementia (2023) 19 (S24) DOI: 10.1002/alz.082794
Snippet: Alamar, NULISA, NULISAseq and ARGO are trademarks of Alamar Biosciences, Inc. All other trademarks and/or service marks not owned by Alamar that appear are the property of their
NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing
Feng, Beer, Hao et al
Nat Commun (2023) 14 (1), 7238 DOI: 10.1038/s41467-023-42834-x
Feng, Beer, Hao et al
Nat Commun (2023) 14 (1), 7238 DOI: 10.1038/s41467-023-42834-x
Cited by 241
Snippet: ), streptavidin-coated paramagnetic beads (streptavidin beads), Elution Buffer 2 (EB2), Ligation Master Mix (LMM), were developed or commercially sourced by Alamar Biosciences
NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing
Feng, Beer, Hao et al
bioRxiv (2023)
Feng, Beer, Hao et al
bioRxiv (2023)
Cited by 7
Snippet: To demonstrate its performance and utility, we developed a 200-plex NULISA targeting 124 on the NULISA technology described herein have been filed by Alamar Biosciences
Detection and quantification of post-translational modifications in non-invasive samples
Baudin, Fjellstrom, Kraft et al
Report (2023)
Baudin, Fjellstrom, Kraft et al
Report (2023)
Snippet: The soon-to-be-released technology NULISA, with promising values in sensitivity and dynamic range, is also investigated here. Additionally, a written ethical analysis regarding the
Showing 1-6 of 6 papers.
Powered by BizGenius